Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that the first patient has been dosed in ...
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related ...
Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in a robust, two-part studyFirst-in-class therapeutic ...
Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...
Third drug candidate from Tenvie’s product engine to enter clinical development in 2026TNV313 joins TNV262 to give Tenvie two clinical-stage, ...
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe ...
Biomea Fusion, Inc. ( BMEA) is scheduled to release Phase I GLP-131 data for its investigational obesity candidate BMF-650 today, October 13, 2026, with shares rising 6.44% to $1.44 in premarket ...
The poster is scheduled for October 22, 2026, during the American Society of Nephrology's Kidney Week in Denver. The program ...
Antwerp, Belgium, October 13, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that the first patient has been dosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results